346 related articles for article (PubMed ID: 33172177)
21. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
[TBL] [Abstract][Full Text] [Related]
22. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
23. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
24. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.
Hess AR; Seftor EA; Gruman LM; Kinch MS; Seftor RE; Hendrix MJ
Cancer Biol Ther; 2006 Feb; 5(2):228-33. PubMed ID: 16481735
[TBL] [Abstract][Full Text] [Related]
25. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer.
Maeda T; Murata M; Chiba H; Takasawa A; Tanaka S; Kojima T; Masumori N; Tsukamoto T; Sawada N
Prostate; 2012 Mar; 72(4):351-60. PubMed ID: 21656836
[TBL] [Abstract][Full Text] [Related]
26. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
27. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
28. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
29. Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury.
Carpenter TC; Schroeder W; Stenmark KR; Schmidt EP
Am J Respir Cell Mol Biol; 2012 Jan; 46(1):40-7. PubMed ID: 21799118
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
[TBL] [Abstract][Full Text] [Related]
31. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland.
Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z
J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804
[TBL] [Abstract][Full Text] [Related]
32. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
33. A novel PAK4-CEBPB-CLDN4 axis involving in breast cancer cell migration and invasion.
Wang F; Gao Y; Tang L; Ning K; Geng N; Zhang H; Li Y; Li Y; Liu F; Li F
Biochem Biophys Res Commun; 2019 Apr; 511(2):404-408. PubMed ID: 30808546
[TBL] [Abstract][Full Text] [Related]
34. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
Xu Q; Lin WC; Petit RS; Groves JT
Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062
[TBL] [Abstract][Full Text] [Related]
35. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade.
Pratt RL; Kinch MS
Oncogene; 2002 Oct; 21(50):7690-9. PubMed ID: 12400011
[TBL] [Abstract][Full Text] [Related]
36. Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell carcinomas.
Nakashima C; Yamamoto K; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Kawahara I; Nishiguchi Y; Mori T; Kondoh M; Luo Y; Kirita T; Kuniyasu H
Oncotarget; 2020 Jan; 11(4):309-321. PubMed ID: 32064037
[TBL] [Abstract][Full Text] [Related]
37. A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis.
Bao Y; Wang Z; Liu B; Lu X; Xiong Y; Shi J; Li P; Chen J; Zhang Z; Chen M; Wang L; Wu Z
Oncogene; 2019 Feb; 38(6):881-895. PubMed ID: 30177838
[TBL] [Abstract][Full Text] [Related]
38. Truncated EphA2 likely potentiates cell adhesion via integrins as well as infiltration and/or lodgment of a monocyte/macrophage cell line in the red pulp and marginal zone of the mouse spleen, where ephrin-A1 is prominently expressed in the vasculature.
Konda N; Saeki N; Nishino S; Ogawa K
Histochem Cell Biol; 2017 Mar; 147(3):317-339. PubMed ID: 27665280
[TBL] [Abstract][Full Text] [Related]
39. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
[TBL] [Abstract][Full Text] [Related]
40. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
Gabig TG; Waltzer WC; Whyard T; Romanov V
Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
